Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 97Unknown 23Terminated 14Recruiting 3Active not recruiting 2Withdrawn 1Enrolling by invitation 1

Sponsor Class

OTHER 35INDUSTRY 5NETWORK 3NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasms 14Multiple Myeloma 11Lymphoma 11Breast Neoplasms 10Melanoma 7Neoplasm Metastasis 6Colorectal Neoplasms 6Sarcoma 5Ovarian Neoplasms 5Lung Neoplasms 5Leukemia 5Colonic Neoplasms 5Carcinoma, Hepatocellular 5Brain Neoplasms 5Triple Negative Breast Neoplasms 4Pancreatic Neoplasms 4Hematologic Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Uterine Cervical Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Neuroblastoma 3Neoplasms, Plasma Cell 3Mesothelioma, Malignant 3Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Liver Neoplasms 3Leukemia, Myeloid, Acute 3Glioblastoma 3

Interventions

fludarabine phosphate 1Cyclophosphamide 1B3(Fv)-PE38KDEL recombinant immunotoxin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × NIH × Hodgkin Disease × Clear all
NCT00389506 2012-03-16

Fludarabine and Cyclophosphamide Followed By LMB-2 Immunotoxin in Treating Patients With Hodgkin's Lymphoma

National Institutes of Health Clinical Center (CC)

Phase NA Withdrawn
Lymphoid

Hodgkin Disease, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡